Top

Published in:

01-06-2015 | Original Article

Association of ubiquitin carboxy-terminal hydrolase-L1 in cerebrospinal fluid with clinical severity in a cohort of patients with Guillain–Barré syndrome

Authors: Satoshi Nagamine, Yuuki Fujiwara, Toshio Shimizu, Akihiro Kawata, Keiji Wada, Eiji Isozaki, Tomohiro Kabuta

Published in: Neurological Sciences | Issue 6/2015

Abstract

Guillain–Barré syndrome (GBS) is an acute immune-mediated polyneuropathy. Although its pathogenic mechanism has been revealed and various therapeutic trials have been performed, a proportion of patients experience the severe sequelae associated with GBS. In this paper, we investigated whether the amount of the neuron-specific protein, ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), in the cerebrospinal fluid of patients with GBS was correlated with the clinical course of the disease. UCH-L1 protein levels were greater in patients with GBS than in controls. The patients with GBS whose UCH-L1 protein levels were higher than those of the controls presented with more severe symptoms at peak. UCH-L1 protein levels tended to become elevated as the total protein levels were increased; however, elevated UCH-L1 without an increase in total protein might be correlated with severe disease course (bedridden or ventilator supported). These results suggest that UCH-L1 could be a biomarker associated with the severity of the disease at the acute phase of GBS.

Available only for authorised users

McGrogan A, Madle GC, Seaman HE, de Vries CS (2009) The epidemiology of Guillain–Barre syndrome worldwide. A systematic literature review. Neuroepidemiology 32(2):150–163. doi:10.1159/000184748 PubMedCrossRef

Kuwabara S (2007) Guillain–barre syndrome. Curr Neurol Neurosci Rep 7(1):57–62PubMedCrossRef

Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (1995) Guillain–Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118(Pt 3):597–605PubMedCrossRef

Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (1993) A bacterium lipopolysaccharide that elicits Guillain–Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 178(5):1771–1775PubMedCrossRef

Kuwabara S, Yuki N (2013) Axonal Guillain–Barre syndrome: concepts and controversies. Lancet Neurol 12(12):1180–1188PubMedCrossRef

Shahrizaila N, Yuki N (2013) Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry 84(5):576–583PubMedCrossRef

Rajabally YA, Uncini A (2012) Outcome and its predictors in Guillain–Barre syndrome. J Neurol Neurosurg Psychiatry 83(7):711–718PubMedCrossRef

Brettschneider J, Petzold A, Sussmuth S, Tumani H (2009) Cerebrospinal fluid biomarkers in Guillain–Barre syndrome—where do we stand? J Neurol 256(1):3–12PubMedCrossRef

Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123(5):773–786PubMedCrossRef

10.

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395(6701):451–452PubMedCrossRef

11.

Bilguvar K, Tyagi NK, Ozkara C, Tuysuz B, Bakircioglu M, Choi M, Delil S, Caglayan AO, Baranoski JF, Erturk O, Yalcinkaya C, Karacorlu M, Dincer A, Johnson MH, Mane S, Chandra SS, Louvi A, Boggon TJ, Lifton RP, Horwich AL, Gunel M (2013) Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc Natl Acad Sci USA 110(9):3489–3494PubMedCentralPubMedCrossRef

12.

Day IN, Thompson RJ (2010) UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol 90(3):327–362. doi:10.1016/j.pneurobio.2009.10.020 PubMedCrossRef

13.

Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM (1978) Controlled trial prednisolone in acute polyneuropathy. Lancet 2(8093):750–753PubMedCrossRef

14.

Kabuta T, Setsuie R, Mitsui T, Kinugawa A, Sakurai M, Aoki S, Uchida K, Wada K (2008) Aberrant molecular properties shared by familial Parkinson’s disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1. Hum Mol Genet 17(10):1482–1496PubMedCrossRef

15.

Nagamine S, Kabuta T, Furuta A, Yamamoto K, Takahashi A, Wada K (2010) Deficiency of ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) leads to vulnerability to lipid peroxidation. Neurochem Int 57(2):102–110. doi:10.1016/j.neuint.2010.04.015 PubMedCrossRef

16.

Yuki N, Yoshino H, Sato S, Miyatake T (1990) Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 40(12):1900–1902PubMedCrossRef

17.

Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, Ueda S, Kasama T, Ohnishi A, Hayashi S, Takahashi H, Kamijo M, Hirata K (2001) Animal model of axonal Guillain–Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 49(6):712–720PubMedCrossRef

18.

Okuyama H (1975) Mechanism of increase of the cerebrospinal fluid (CSF) protein content in Guillain–Barre syndrome. Study using RISA in evaluation of diffusion within CSF cavity and transport of CSF to circulating plasms. Rinsho Shinkeigaku 15(11):817–826PubMed

19.

Arnaoutakis GJ, George TJ, Wang KK, Wilson MA, Allen JG, Robinson CW, Haggerty KA, Weiss ES, Blue ME, Talbot CC Jr, Troncoso JC, Johnston MV, Baumgartner WA (2011) Serum levels of neuron-specific ubiquitin carboxyl-terminal esterase-L1 predict brain injury in a canine model of hypothermic circulatory arrest. J Thorac Cardiovasc Surg 142(4):902–910. doi:10.1016/j.jtcvs.2011.06.027 (e901)PubMedCentralPubMedCrossRef

20.

Petzold A, Brettschneider J, Jin K, Keir G, Murray NM, Hirsch NP, Itoyama Y, Reilly MM, Takeda A, Tumani H (2009) CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain–Barre syndrome. Muscle Nerve 40(1):42–49PubMedCrossRef

21.

Massaro ME, Rodriguez EC, Pociecha J, Arroyo HA, Sacolitti M, Taratuto AL, Fejerman N, Reisin RC (1998) Nerve biopsy in children with severe Guillain–Barre syndrome and inexcitable motor nerves. Neurology 51(2):394–398PubMedCrossRef

22.

Wang XK, Zhang HL, Meng FH, Chang M, Wang YZ, Jin T, Mix E, Zhu J (2013) Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain–Barre syndrome. Neurol Sci 34(5):655–661PubMedCrossRef

23.

Papa L, Akinyi L, Liu MC, Pineda JA, Tepas JJ 3rd, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton SC, Hannay HJ, Demery JA, Brophy GM, Layon J, Robertson CS, Hayes RL, Wang KK (2010) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38(1):138–144. doi:10.1097/CCM.0b013e3181b788ab PubMedCentralPubMedCrossRef

24.

Mondello S, Palmio J, Streeter J, Hayes RL, Peltola J, Jeromin A (2012) Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol 12:85. doi:10.1186/1471-2377-12-85 PubMedCentralPubMedCrossRef

Title: Association of ubiquitin carboxy-terminal hydrolase-L1 in cerebrospinal fluid with clinical severity in a cohort of patients with Guillain–Barré syndrome
Authors: Satoshi Nagamine
Yuuki Fujiwara
Toshio Shimizu
Akihiro Kawata
Keiji Wada
Eiji Isozaki
Tomohiro Kabuta
Publication date: 01-06-2015
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 6/2015
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-015-2137-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of ubiquitin carboxy-terminal hydrolase-L1 in cerebrospinal fluid with clinical severity in a cohort of patients with Guillain–Barré syndrome

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2015

A systematic review and meta-analysis of cognitive behavioral and psychodynamic therapy for depression in Parkinson’s disease patients

An unusual case of isoniazid toxicity

Cerebrospinal fluid and lumbar puncture: the story of a necessary procedure in the history of medicine

Observation of cerebral aneurysm wall thickness using intraoperative microscopy: clinical and morphological analysis of translucent aneurysm

Diffuse leukoencephalopathy due to lymphomatosis cerebri: a clinicopathological report

Predicting outcomes from radiosurgery for intracranial arteriovenous malformations: effect of embolization, prior hemorrhage, and nidus anatomy